Product Code: IRTNTR7888
About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.
Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.
Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
Key vendors
- Amgen
- Bayer
- Bristol-Myers Squibb
- Chugai Pharmaceuticals
- Merck
- Sanofi
Other Prominent Vendors
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- AVEO Oncology
- Bavarian Nordic
- Biothera
- Boehringer Ingelheim
- Boston Biomedical
- Cancer Prevention Pharmaceuticals
- Celator Pharmaceuticals
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- EpicentRx
- GlaxoSmithKline
- Hutchison Medipharma
- Immodulon Therapeutics
- Immunomedics
- MacroGenics
- Merrimack Pharmaceuticals
- MolMed
- Mologen
- Morphotek
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- PledPharma
- Precision Biologics
- PsiOxus Therapeutics
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva Pharmaceuticals
- ThromboGenics
- Xbiotech
- Yakult Honsha
Key market driver
- Increase in aging population
- For a full, detailed list, view our report
Key market challenge
- Unknown disease etiology
- For a full, detailed list, view our report
Key market trend
- Rise in public awareness
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Vectibix
PART 03: Product profiles
- Stivarga
- Erbitux
- Xeloda
- Avastin
- Zaltrap
PART 04: Market research methodology
- Research methodology
- Economic indicators
PART 05: Introduction
PART 06: Disease overview
- Understanding the disease
- High risk factors
- Signs and symptoms
- Pathophysiology
- Diagnosis
- Staging
- Biomarker testing
- Epidemiology
- Treatment
PART 07: Pipeline portfolio
- Information on pipeline candidates
PART 08: Market landscape
- Market overview
- Market size and forecast
- Colorectal cancer therapeutics market in Japan
- Colorectal cancer therapeutics market in China
- Five forces analysis
PART 09: Market segmentation by based on the type of molecules
- Small molecules
- Biologics
PART 10: Market segmentation by route of administration
PART 11: Market segmentation by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other prominent vendors
- Amgen
PART 18: Key vendor analysis
- Bayer HealthCare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi
PART 19: Appendix
PART 20: Explore Technavio
List of Exhibits
- Exhibit 01: Product offerings
- Exhibit 02: High risk factors for colorectal cancer
- Exhibit 03: Signs and symptoms of colorectal cancer
- Exhibit 04: Diagnostic tests for colorectal cancer
- Exhibit 05: Staging for colon cancer
- Exhibit 06: Staging for rectal cancer
- Exhibit 07: Types of genes
- Exhibit 08: Estimated incidence, mortality, and five-year prevalence per 100,000 in APAC 2012
- Exhibit 09: Colorectal cancer mortality rates in APAC 2012 (rate per 100,000 population)
- Exhibit 10: Incidence rates of colorectal cancer in Asia, 2011 (rate per 100,000 population)
- Exhibit 11: Estimated incidence in adult population in APAC 2012
- Exhibit 12: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, males
- Exhibit 13: Colorectal cancer incidence and mortality rates in top seven countries in Asia regions, 2008, females
- Exhibit 14: Treatment options for colorectal cancer
- Exhibit 15: Types of surgical procedure for colorectal cancer
- Exhibit 16: Types of radiation therapy for colorectal cancer
- Exhibit 17: Types of targeted therapy
- Exhibit 18: Summary of approved cancer drugs for colon cancer
- Exhibit 19: Pipeline molecules for colorectal cancer
- Exhibit 20: Colorectal cancer therapeutics market in APAC ($ billions)
- Exhibit 21: Colorectal cancer therapeutics market in Japan 2014-2019 ($ billions)
- Exhibit 22: Colorectal cancer therapeutics market in China 2014-2019 ($ millions)
- Exhibit 23: Five forces analysis
- Exhibit 24: Colorectal cancer therapeutics market in APAC segmented by molecule type
- Exhibit 25: Colorectal cancer therapeutics market in APAC segmented by route of administration
- Exhibit 26: Summary of chemotherapy drugs for the treatment of colorectal cancer
- Exhibit 27: Use of branded targeted therapies in China and Japan 2013
- Exhibit 28: Drivers of colorectal cancer therapeutics market in APAC
- Exhibit 29: Impact of drivers
- Exhibit 30: Challenges of colorectal cancer therapeutics market in APAC
- Exhibit 31: Impact of drivers and challenges
- Exhibit 32: Trends of colorectal cancer therapeutics market in APAC
- Exhibit 33: Vectibix: YoY revenue and growth rate in Japan 2011-2013 ($ millions)
- Exhibit 34: Amgen: Key takeaways
- Exhibit 35: Bayer: Key takeaways
- Exhibit 36: Bristol-Myers Squibb: Key takeaways
- Exhibit 37: Avastin: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
- Exhibit 38: Xeloda: YoY revenue and growth rate in Japan 2010-2014 ($ millions)
- Exhibit 39: Chugai Pharmaceutical: Key takeaways
- Exhibit 40: Merck: Key takeaways
- Exhibit 41: Sanofi: Key takeaways
- Exhibit 42: Amgen: Business segmentation by revenue 2014
- Exhibit 43: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
- Exhibit 44: Amgen: Geographical segmentation by revenue 2014
- Exhibit 45: Bayer HealthCare: Business segmentation by revenue 2014
- Exhibit 46: Bayer HealthCare: Business segmentation by revenue 2013 and 2014 ($ billions)
- Exhibit 47: Bayer HealthCare: Geographical segmentation by revenue 2014
- Exhibit 48: Bristol-Myers Squibb: Products segmentation by revenue FY2014
- Exhibit 49: Bristol-Myers Squibb: Revenue comparison by product segmentation by FY2013 and FY2014
- Exhibit 50: Bristol-Myers Squibb: Geographical segmentation by FY2014 ($ millions)
- Exhibit 51: Bristol-Myers Squibb: Revenue comparison by geographical segment by FY2013 and FY2014 ($ millions)
- Exhibit 52: Chugai Pharmaceuticals: Business segmentation by revenue 2014 (therapeutics)
- Exhibit 53: Chugai Pharmaceuticals: Geographical segmentation by revenue 2014
- Exhibit 54: Merck: Business segmentation by revenue 2014
- Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
- Exhibit 56: Merck: Geographical segmentation by revenue 2014
- Exhibit 57: Sanofi: Business segmentation by revenue 2014
- Exhibit 58: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
- Exhibit 59: Sanofi: Geographical segmentation by revenue 2014
